Order Article Reprints

Nokihara H, Kijima T, Yokoyama T, Kagamu H, Suzuki T, Mori M, Santorelli ML, Taniguchi K, Kamitani T, Irisawa M, et al. Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan. Cancers. 2022; 14(12):2846. https://doi.org/10.3390/cancers14122846

Nokihara, Hiroshi, Takashi Kijima, Toshihide Yokoyama, Hiroshi Kagamu, Takuji Suzuki, Masahide Mori, Melissa L. Santorelli, Kazuko Taniguchi, Tetsu Kamitani, Masato Irisawa, and et al. 2022. "Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan" Cancers 14, no. 12: 2846. https://doi.org/10.3390/cancers14122846

Nokihara, H., Kijima, T., Yokoyama, T., Kagamu, H., Suzuki, T., Mori, M., Santorelli, M. L., Taniguchi, K., Kamitani, T., Irisawa, M., Kanda, K., Abe, M., Burke, T., & Goto, Y. (2022). Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan. Cancers, 14(12), 2846. https://doi.org/10.3390/cancers14122846